Anti-inflammatory effects of icariin in the acute and chronic phases of the mouse pilocarpine model of epilepsy
European Journal of Pharmacology · 2023
DOI: 10.1016/j.ejphar.2023.176141 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pharmacology, 2023. Verfasst von Jing Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China; National Clinical Research Center for Geriatric …. Hauptthemen laut MEDLINE: Pilocarpine, Epilepsy. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 61 Literaturangaben. Gefördert von: Natural Science Foundation of Hunan Province, National Key Research and Development Program of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Neuroinflammation mediated by microglia made a significant contribution in the pathophysiology of epilepsy. Icariin (ICA), a bioactive ingredient isolated from Epimedium, has been shown to present both antioxidant and anti-inflammatory properties. This study was to explore the potential therapeutic effects of icariin on mouse pilocarpine model of epilepsy and its underlying mechanisms in vivo and in vitro. To this end, we firstly measured the serum concentrations of the proinflammatory cytokines IL-1β and IL-6 from patients with temporal lobe epilepsy and found that patients with a higher seizure frequency showed correspondingly higher inflammatory reaction. Mouse pharmacokinetic study, transmembrane transportation assay, and cell viability assay collectively demonstrated that ICA was able to cross the blood-brain barrier and has good biocompatibility. The acute and chronic epilepsy models were next established in a pilocarpine mouse model of acquired epilepsy. Icariin has been identified that it could cross the blood-brain barrier and enter the hippocampus to exhibit therapeutic effects. ICA treatment dramatically promoted microglial polarization to the M2 phenotype in epilepsy mice both in the acute and chronic phases. Reduced release of M1-associated proinflammatory factors, such as IL-1β and IL-6, corroborates the altered glial cell polarization. Furthermore, ICA alleviated seizure intensity and mortality in acute phase epileptic mice. Models in the chronic group also showed improved general condition, cognition ability, and memory function after ICA treatment. Taken together, our research strongly suggested that icariin has the potential to treat epilepsy via inhibiting neuroinflammation by promoting microglial polarization to the M2 phenotype.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China; National Clinical Research Center for Geriatric Disorders (Xiangya Hospital), Central South University, Changsha, Huna…
- Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, China.
Förderung
- Natural Science Foundation of Hunan Province
- National Key Research and Development Program of China
- National Natural Science Foundation of China
Zitieren
APA
Wang, J., Liu, Y., Wu, Y., Yang, K., Yang, K., Yan, L., & Feng, L. (2023). Anti-inflammatory effects of icariin in the acute and chronic phases of the mouse pilocarpine model of epilepsy. European Journal of Pharmacology. https://doi.org/10.1016/j.ejphar.2023.176141
Vancouver
Wang J, Liu Y, Wu Y, Yang K, Yang K, Yan L, et al. Anti-inflammatory effects of icariin in the acute and chronic phases of the mouse pilocarpine model of epilepsy. European Journal of Pharmacology. 2023. doi:10.1016/j.ejphar.2023.176141
BibTeX
@article{Wang2023,
author = {Wang, Jing and Liu, Yunyi and Wu, Yuanxia and Yang, Ke and Yang, Kaiyi and Yan, Luzhe and Feng, Li},
title = {Anti-inflammatory effects of icariin in the acute and chronic phases of the mouse pilocarpine model of epilepsy},
journal = {European Journal of Pharmacology},
year = {2023},
doi = {10.1016/j.ejphar.2023.176141}
}
EUVIMED